Tagged with Americas

Mexico In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract foreign biopharma investment. By promising international companies a better chance at winning government tenders, Sheinbaum hopes to increase domestic manufacturing,…

Puerto Rico Already a solid hub for biopharma manufacturing and logistics, Puerto Rico is moving to sharpen its position in the evolving US reshoring landscape and attract new investment. Under the banner “Made in Puerto Rico is Made in the USA,” Governor Jenniffer Gonzalez-Colon is promoting the island’s unique value as both…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Puerto Rico Sebastián Negrón Reichard, Secretary of the Department of Economic Development and Commerce, sees Puerto Rico’s current economic landscape as one of immense opportunity, particularly with the US government’s focus on reshoring. With a skilled workforce, strategic location, and historical economic strengths, Puerto Rico is poised to contribute significantly to national…

Puerto Rico Umberto Donato, president of DDD Group, a construction firm specialising in complex sectors including pharma, reflects on the company’s growth over the past decade and the role of infrastructure and facility design in attracting investment to Puerto Rico. He also discusses evolving client expectations, sustainability, the factors shaping the construction…

Americas Diego Salas from the Latin American Federation of the Pharmaceutical Industry (FIFARMA) and Carlos Felipe Escobar Roa from the Instituto de Prospectiva e Innovacion en Salud (INNOS), writing in the May 2025 edition of DIA’s Global Forum magazine, discuss the findings of a pioneering report launched at the end of…

Brazil After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the Japanese drugmaker, Rodriguez will be taking on a country full of opportunities and challenges. With more dengue cases than anywhere…

Puerto Rico Isla Frio provides state-of-the-art temperature-controlled storage solutions for pharma, among other industries. Founder Geoffrey Parrillo discusses the company’s efforts to adapt to the demands of the pharma industry, offering solutions such as FDA-approved validated rooms. He also outlines Isla Frio’s unique real-time tracking technology, weighs in on the steps Puerto Rico…

Global Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With bold investments in R&D and AI-driven innovation, the French pharma is positioning itself as a pure-play biopharma leader. In conversation…

Puerto Rico Puerto Rico leads all US jurisdictions in biopharmaceutical exports, shipping to over 120 countries. With a rapidly expanding life sciences sector and growing pharma logistics capabilities, the island is positioning itself as a global hub—but industry leaders say there’s still work to be done.   Life Sciences and Logistics Dynamo…

LatAm A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4 million investment in Brazil, and SteinCares’ plasma derivatives deal with Biotest.   Record dengue outbreak in Americas kills 7,700 this…

Puerto Rico CytoImmune, founded in 2017 and established in Puerto Rico in 2020, is focused on developing immune-based therapies using proprietary natural killer (NK) cells. CEO Dr José Eduardo Vidal discusses the biotech’s innovative approach, the access promise of allogeneic NK cells as opposed to T-cell therapies, the advantages of setting up…